These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2533180)

  • 1. Defibrotide and peripheral obliterative arterial disease: preliminary data.
    Arosio E; Pancera P; Zannoni M; Arcaro G; Priante F; Lechi A
    Int J Clin Pharmacol Ther Toxicol; 1989 Nov; 27(11):526-9. PubMed ID: 2533180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot evaluation of the effect of defibrotide in patients affected by peripheral arterial occlusive disease.
    Sabbá C; Zupo V; Dina F; Nazzari M; Albano O
    Int J Clin Pharmacol Ther Toxicol; 1988 May; 26(5):249-52. PubMed ID: 3045026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of defibrotide on physical performance and hemorheologic picture in patients with peripheral arteriopathy.
    Marrapodi E; Leanza D; Giordano S; Nazzari M; Corsi C
    Clin Trials Metaanal; 1994 Apr; 29(1):21-30. PubMed ID: 10150182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease.
    Strano A; Fareed J; Sabbá C; Albano O; Allegra C; Carlizza A; Binaghi F; Fronteddu F; Del Guercio R; Arpaia MR
    Semin Thromb Hemost; 1991; 17 Suppl 2():228-34. PubMed ID: 1948094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical experience in patients with chronic peripheral obliterating arteriopathy: defibrotide versus definite molecular weight heparan sulfate (MW 7500-15000 dalton)].
    Michelini S; Micci A; Failla A; Grechi G; Iantaffi A
    Minerva Cardioangiol; 1996; 44(1-2):33-7. PubMed ID: 8767620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of defibrotide after oral and parenteral administration in patients with peripheral obliterative arterial disease (POAD).
    Craveri A; Tornaghi G; Ranieri R; Stanzani M; Landi G; Paganardi L; Passaretti B; Gallo E
    Int Angiol; 1990; 9(4):274-7. PubMed ID: 2099963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of chronic obliterative arteriopathy of the legs in the second Fontaine's stage. Personal experience with a buflomedil-pentoxifylline-defibrotide combination].
    Marci M; Albiani B; Ricci M; Russo F
    Clin Ter; 1995 Mar; 146(3):211-4. PubMed ID: 7789083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of oral and intravenous defibrotide on blood viscosity in patients with peripheral obliterative arterial disease.
    Belfiglio A; Traietti P; Bologna E; Salvo G
    Clin Ther; 1989; 11(4):479-84. PubMed ID: 2776165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
    Arosio E; Sardina M; Prior M; De Marchi S; Zannoni M; Bianchini C
    Eur Rev Med Pharmacol Sci; 1998; 2(2):53-9. PubMed ID: 10229559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of defibrotide on peripheral obliterative vascular diseases.
    Ulutin ON; Ilhan-Berkel N; Tunali H; Ozer M; Balkuv-Ulutin S; Onsel C; Urgancioğlu I
    Haemostasis; 1986; 16 Suppl 1():59-62. PubMed ID: 3754837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravenous pentoxifylline in Fontaine stage II and III peripheral arterial diseases].
    Giansante C; Di Chiara A; Fiotti N; Mauri F; Sorrentino A; Spanghero M; Tomasin L; Calabrese S
    Clin Ter; 1990 Sep; 134(5):301-5. PubMed ID: 2149312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease.
    Allegra C; Antignani PL; Schachter I; Koverech A; Messano M; Virmani A
    Ann Vasc Surg; 2008; 22(4):552-8. PubMed ID: 18502605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of walking distance by defibrotide in patients with intermittent claudication--results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study.
    Violi F; Marubini E; Coccheri S; Nenci GG
    Thromb Haemost; 2000 May; 83(5):672-7. PubMed ID: 10823260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of deep venous thrombosis with defibrotide. Pilot study].
    Sammarco M; Garofalo M; Nazzari M
    Minerva Med; 1988 Jun; 79(6):495-7. PubMed ID: 2967927
    [No Abstract]   [Full Text] [Related]  

  • 15. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
    Qureshi A; Marshall L; Lancaster D
    Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of intermittent claudication with defibrotide or mesoglycan. A double blind study.
    Laurora G; Ambrosoli L; Cesarone MR; De Sanctis MT; Incandela L; Marelli C; Belcaro G
    Panminerva Med; 1994 Jun; 36(2):83-6. PubMed ID: 7831064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic occlusive arterial disease with pentoxifylline: changes in clinical and haemodynamic parameters.
    Schweiger H; Ortmeier CJ
    Pharmatherapeutica; 1989; 5(5):298-304. PubMed ID: 2526340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prostacyclin and pentoxifylline in the treatment of patients with inoperable occlusions of the peripheral arteries of the lower extremities].
    Maksimović ZV
    Srp Arh Celok Lek; 1999; 127(7-8):249-53. PubMed ID: 10624398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention of deep venous thrombosis with defibrotide in chest surgery. Controlled multicenter study versus heparin].
    Rizzi A; Radaelli F; Pisano M; Orro S; Nazzari M; Ratti G; Giobbe R; Maggi G
    Minerva Med; 1987 Jun; 78(11):745-50. PubMed ID: 3295599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of short-term defibrotide treatment of patients with atherosclerosis obliterans of the lower limbs.
    Avellone G; Mandalà V; Pinto A; Martino A; Strano A
    Haemostasis; 1986; 16 Suppl 1():55-8. PubMed ID: 2423422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.